{
    "clinical_study": {
        "@rank": "46946", 
        "acronym": "SIEG", 
        "arm_group": {
            "arm_group_label": "Irinotecan plus epirubicin", 
            "arm_group_type": "Experimental", 
            "description": "Irinotecan(Camptosar)150mg /m2 d1,\uff08intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment * 6 cycles as the second line chemoregime for advanced gastric cancer"
        }, 
        "brief_summary": {
            "textblock": "This study is to determine the response rate and safety profile of irinotecan plus\n      epirubicin as the second-line chemotherapy for advanced gastric cancer and fully evaluate\n      the feasibility and effectiveness of the regime."
        }, 
        "brief_title": "The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Stage IV Gastric Cancer With Metastasis", 
        "condition_browse": {
            "mesh_term": [
                "Stomach Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The main  purposes: to determine the progression-free survival (PFS) and overall survival\n      (OS) of gastric cancer patients given irinotecan + epirubicin as second-line treatment, who\n      are at Stage IV with disease progressed or recurred after first-line chemotherapy failed, ,\n\n      The Secondary purposes: to determine disease control rate (Disease Control Rate, DCR), the\n      objective response rate (Object Response rate, ORR)  and  the Quality of life (Quality Of\n      Life, QOL)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Aged between 18 to 70 years\n\n          -  The pathologically confirmed gastric adenocarcinoma and the failure of first-line\n             chemotherapy\n\n          -  Measurable lesions outside the stomach\n\n          -  ECOG(Eastern Cooperative Oncology Group ) score between 0 to 1\n\n          -  Expected survival time of at least 3 months\n\n          -  Subjects receiving treatment for other damage caused has been restored, which it\n             accepted the nitroso or mitomycin interval> 6 weeks, the acceptance of other\n             cytotoxic drugs, radiotherapy or surgery> = 4 weeks, and the wound has completely\n             healed. No bleeding, no nervous system transferred\n\n          -  Blood and organ function was normal\n\n        Exclusion criteria:\n\n          -  Comorbid with other malignant tumors\n\n          -  Pregnant and lactating women\n\n          -  with the disease of endangering  patient's safety and affecting the completion of the\n             study\n\n          -  Patients suffering from high blood pressure by antihypertensive treatment  cannot\n             control (systolic blood pressure> 140mmhg, diastolic blood pressure> 90mmhg,) there\n             is more than Class I and Class I arrhythmia coronary heart disease, with more than\n             Class I heart dysfunction\n\n          -  Major organ failure, such as decompensated heart and lung failure, liver failure,\n             renal failure and patients with intestinal obstruction ipate in other clinical trials\n             of patients  in the past four weeks\n\n          -  Participated in clinical trials with other drugs or using other drugs  during past 4\n             weeks\n\n          -  Lesions which can't be measured such as pleural effusion, ascites, peritoneal cancer\n             lesions, diffuse liver and bone metastases violation, brain metastasis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01964027", 
            "org_study_id": "SIEG"
        }, 
        "intervention": {
            "arm_group_label": "Irinotecan plus epirubicin", 
            "description": "Irinotecan(Camptosar)150mg /m2 d1,\uff08intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment * 6 cycles as the second line chemoregime for advanced gastric cancer", 
            "intervention_name": "second line chemoregime for advanced gastric cancer", 
            "intervention_type": "Drug", 
            "other_name": "irinotecan plus epirubicin"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Epirubicin", 
                "Irinotecan"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "second line chemoregime", 
            "gastric cancer"
        ], 
        "lastchanged_date": "October 14, 2013", 
        "location": {
            "contact": {
                "email": "yueyinpan@gmail.com", 
                "last_name": "Yueyin Pan, MD", 
                "phone": "865512922987"
            }, 
            "facility": {
                "address": {
                    "city": "Hefei", 
                    "country": "China", 
                    "state": "Anhui", 
                    "zip": "230032"
                }, 
                "name": "Department of Oncology,The First Affiliated Hospital of Anhui Medical University"
            }, 
            "investigator": {
                "last_name": "Hu Liu, MD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer", 
        "overall_contact": {
            "email": "yueyinpan@gmail.com", 
            "last_name": "Yueyin Pan, MD", 
            "phone": "865512922987"
        }, 
        "overall_official": {
            "affiliation": "Anhui Medical University", 
            "last_name": "Yueyin Pan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluation progression-free survival (PFS) and overall survival (OS)\nRECIST(Response Evaluation Criteria In Solid Tumors)1.1:\nComplete response (CR)\nPartial response (PR)\nStable disease(SD) and progression disease(PD)\nCR + PR is efficient.", 
            "measure": "PFS and OS", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01964027"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Anhui Medical University", 
            "investigator_full_name": "Pan Yueyin", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Anhui Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Anhui Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}